Biomarkers - Resources

Explore our brands

Our brands bring together the industry's most influential leaders and scientific experts, inspiring thought-provoking and insightful content that offers a unique perspective on R&D trends and challenges.

13/05/24 - A test that identifies Zika distinct from dengue could make a definite impact to expectant mothers and reproductive-age women that are at risk from the mosquito-borne disease.

Explore our brands

Content Type

Subjects

Keywords

Biomarkers for Clinical Development

Keytruda sees Trial Success in Treating Endometrial Cancer Patients

The immunotherapeutic was successfully trialled in patients with endometrial cancer, the results of which Merck said it would discuss with regulatory authorities.

Biomarkers for Clinical Development

Eli Lilly Focus on Phase III Trial for Alzheimer’s Treatment Following FDA Fast Lane Setback

The FDA ‘specifically requested’ data from at least 100 patients who received a minimum 12 months’ treatment of Lilly’s drug donanemab before the approval process could progress further.

Biomarkers for Clinical Development

FDA Approves Merck-Developed KEYTRUDA for Non-Small Cell Lung Cancer Therapy

KEYTRUDA demonstrated a clinically meaningful improvement in disease-free survival in patients following surgical resection and platinum-based chemotherapy.

Biomarkers for Drug Discovery & Development

Bioassay Optimisation: How the Pandemic Reshaped International Standards for New Therapeutics

The global race to develop, trial, and distribute a vaccine for Covid-19 may have permanently accelerated the development of future therapeutics, including treatments for cancer.

Biomarkers for Clinical Development

FDA Commits to Increasing Diversity in Clinical Trials

The move follows steps announced by the EMA and the MHRA to ensure clinical trials are more reflective of patient populations.

Biomarkers for Clinical Development

Predicting Parkinson’s Disease with Machine Learning

Understanding machine learning’s role in providing a biomarker for the neurological condition.

Diagnostics

Study Reveals Altered Spontaneous Brain Activity in People with Down Syndrome

A new study has revealed that using functional magnetic resonance techniques shows the differences in the spontaneous activity of the brain in people with Down syndrome compared to the general population.